This article was downloaded by: [The Aga Khan University] On: 27 October 2014, At: 03:42 Publisher: Taylor & Francis Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides and Nucleotides

Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/lncn19

A 5'-Noraristeromycin Enantiomer with Activity Towards Hepatitis B Virus

Katherine L. Seley^a, Stewart W. Schneller^a & Brent Korba^b ^a Department of Chemistry, , Auburn University, Auburn, AL, 36849-5312

^b Georgetown University, Rockville, MD, 20852 Published online: 23 Aug 2006.

To cite this article: Katherine L. Seley , Stewart W. Schneller & Brent Korba (1997) A 5⁷-Noraristeromycin Enantiomer with Activity Towards Hepatitis B Virus, Nucleosides and Nucleotides, 16:12, 2095-2099, DOI: <u>10.1080/07328319708002560</u>

To link to this article: http://dx.doi.org/10.1080/07328319708002560

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at <u>http://www.tandfonline.com/page/terms-and-conditions</u>

A 5'-Noraristeromycin Enantiomer with Activity Towards Hepatitis B Virus

Katherine L. Seley and Stewart W. Schneller* Department of Chemistry, Auburn University, Auburn, AL 36849-5312

and

Brent Korba Georgetown University, Rockville, MD 20852

Abstract

(+)-5'-Noraristeromycin has selective activity against hepatitis B virus (HBV) replication in 2.2.15 cells in culture, while the (-) enantiomer was found to be inactive. A modified synthesis is presented for (+)-5'-noraristeromycin.

Beginning with the synthesis of carbocyclic adenosine (aristeromycin, 1) in 1966,¹ a number of carbocyclic nucleosides have been studied as potential medicinal and biochemical agents.² Several years ago, we reported³ the first carbocyclic nucleoside lacking the C-5' carbon and this commenced concerted investigations by us⁴ and others⁵ into this class of compounds now known as 5'-nor carbocyclic nucleosides. The adenosine derivative (5'-noraristeromycin) has been shown to possess notable antiviral activity (2)^{4b} and anti-trypanosomal activity (3)⁶ with no undesirable toxic side effects. In exploring the antiviral range of 5'-noraristeromycin, enantiomers 2 and 3 were tested for their potential towards hepatitis B virus.



^{*}Author to whom correspondence should be addressed

Copyright © 1997 by Marcel Dekker, Inc.

Chemistry

The synthesis of both 2^7 and 3^8 have been reported and, while the literature method⁷ was used for 2, a more direct route to 3 than previously described⁸ was employed. In that regard, the synthesis of 3 was accomplished by, first, the palladium-catalyzed coupling of 4^8 with N^6 -benzoyladenine⁹ to afford 5. Subsequent debenzoylation of 5 using ammonium hydroxide in methanol to 6 was followed by glycolization with osmium tetroxide to give 3.

Antiviral Results

Antiviral analyses for the inhibition of HBV replication were performed on confluent cultures of the chronically HBV-producing human hepatoblastoma cell line, 2.2.15, as previously described.¹⁰ Cells were treated with 9 consecutive daily doses (medium removed daily) of the agents. Antiviral activity was assessed by dot blot hybridization analysis for reductions in the levels of extracellular HBV virion DNA and cytotoxicity by uptake of neutral red dye.¹⁰ In these analyses, reductions in virion production of less than 3-fold are routinely not statistically significant.¹⁰

(+)-5'-Noraristeromycin (compound **3**) was found to inhibit intracellular HBV replication and virion production in 2.2.15 cells at a concentration significantly below the 50% cytotoxic concentration [CC_{50}] (see Table below). The (-) enantiomer of **3** and the dideoxy intermediate (compound **6**) were inactive against HBV replication.

Experimental. Melting points were recorded on a Meltemp II melting point apparatus and are uncorrected. Combustion analyses were performed by M-H-W Laboratories, Phoenix AZ. ¹H and ¹³C spectra were recorded on a Bruker AC 250 spectrometer (operated at 250 and 62.5 MHz, respectively) all referenced to internal tetramethylsilane (TMS) at 0.0 ppm. The spin multiplicities are indicated by the symbols s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). The optical rotation was measured on a JASCO DIP-370 polarimeter. Reactions were monitored by thin-layer chromatography (TLC) using 0.25 mm Whatman Diamond silica gel 60-F₂₅₄ precoated plates with visualization by irradiation with a Mineralight UVGL-25 lamp or exposure to iodine vapor. Column chromatography was performed on Whatman silica, 230-400 mesh, 60 Å and elution with the indicated solvent system. Yields refer to chromatographically and spectroscopically (¹H and ¹³C NMR) homogeneous materials.

Abbreviations: MeOH, methanol; PPh₃, triphenylphosphine; DMSO, dimethylsulfoxide; DMSO- d_6 , deuterated dimethyl sulfoxide; NH₄OH, ammonium hydroxide; THF, tetrahydrofuran; EtOAc, ethyl acetate; CH₂Cl₂, methylene chloride; NaH, sodium hydride, DMF, dimethylformamide; NMO, 4-methylmorpholine *N*-oxide.



Reaction conditions: *a*, N^6 -benzoyladenine and NaH in DMSO then add $4/(Ph_3P)_4Pd/PPh_3$ in THF at rt then 55°C; *b*, NH₄OH/ MeOH, 120°C, 2 days; *c*, OsO₄/60% aq. 4-methylmorpholine N-oxide in THF/H₂O.

Scheme 1

Table 1

			Extracellular HBV		Intracellular HBV	
		virion DNA		replication intermediates		
Compound	CC ₅₀ (µM)	<u>EC₅₀ (μM)</u>	<u>ΕC₉₀ (μΜ)</u>	<u>ΕC₅₀ (μM)</u>	<u>EC₉₀(µM)</u>	
(+)-3	446 ± 20	1.4 ± 0.1	9.6 ± 0.8	15 ± 1.1	41 ± 3.0	
(-)-3	422 ± 34	>10	>10	-	-	
6	132 ± 12	>10	>10	-	-	

(1S,4R)-N-[9-(4-Hydroxy-2-cyclopentenyl)-9H-purin-6-yl]benz-

amide (5). To a solution of N^6 -benzoyladenine (3.37 g, 14.10 mmol) in anhydrous DMSO (30 mL) was added NaH (95%, 0.39 g, 15.4 mmol). The mixture was stirred for 30 min under an argon atmosphere. To this mixture was added tetrakis(triphenyl-phosphine)palladium (1.01 g, 0.87 mmol), Ph₃P (0.39 g, 1.49 mmol) and a solution of **4**⁸ (2.0 g, 14.08 mmol) in anhydrous THF (30 mL). The mixture was stirred at 55 °C for 2

days. The volatiles were removed by rotary evaporation. The residue was slurried in CH_2Cl_2 and filtered. The filtrate was evaporated, and the residue was purified via column chromatography eluting with EtOAc, followed by EtOAc/MeOH (12:1). Product-containing fractions were combined and evaporated to afford an off-white foam, which was recrystallized with hexane-EtOAc to give 5 (2.65 g, 59 %) as a white solid: mp 159-160°C (lit.⁸ 159-161°C). The spectral data is consistent with that reported⁸ previously for 5. The microanalytical data confirmed the purity of the product.

(1*S*,4*R*)-4-Hydroxy-1-(6-amino-9*H*-purin-9-yl)cyclopent-2-ene (6). A solution of **5** (2.5 g, 7.78 mmol) in 200 mL concentrated ammonia/MeOH (1:1) was sealed in a steel bomb and heated at 100 °C for 2 days. The bomb was cooled. The solvent was removed and the tan residue was triturated in MeOH, filtered and purified via column chromatography eluting with CH₂Cl₂/MeOH (98:2 then 95:5) to afford 1.35 g (80 %) of **6** as an off white solid, mp 189-190 °C; ¹ H NMR (DMSO- d_6) δ 1.73-1.82 (dt, 1H), 2.86-2.95 (m, 1H), 4.75 (br, 1H), 5.51 (m, 1H), 5.60 (d, 1H), 6.20 (d, 1H), 6.22 (d, 1H), 7.32, (br, 2H), 8.11 (s, 1H), 8.19 (s, 1H); ¹³ C NMR (DMSO- d_6) δ 41.14, 57.16, 73.78, 119.03, 130.73, 135.55, 139.32, 148.86, 152.22, 156.06. Calcd. for $C_{10}H_{11}N_5$ O: C, 55.47; H, 5.08; N, 32.11. Found: C, 55.43, H, 5.30, N, 32.20.

(1*R*, 2*S*, 3*R*, 4*S*)-4-(6-Amino-9*H*-purin-9-yl)cyclopentane-1,2,3triol ((+)-3). A solution of 6 (1.35 g, 6.19 mmol) in 50 mL THF/H₂O (10:1) was treated with OsO₄ (100 mg) and NMO (1 mL) and the solution stirred at rt overnight. The solvents were evaporated under reduced pressure and the residue triturated with MeOH, filtered and the tan solid purified further by column chromatography eluting with CH₂Cl₂/MeOH (5:1, then 1:1) to afford 0.86 g (55 %) of **3** as a white solid: mp 251-252 °C; $[\alpha]^{23}_{D}$ +45.869° (*c* 0.14, DMF); ¹ H NMR (DMSO-*d*₆) δ 1.77-1.90 (dq, 1H), 2.57-2.66 (m, 1H), 3.76 (br, 1H), 3.90 (br, 1H), 4.52 (br, 1H), 4.63-4.73 (q, 1H), 4.90 (br s, 1H), 5.02 (br s, 1H), 5.37 (br s, 1H), 7.23 (br s, 2H), 8.12 (s, 1H), 8.16, (s, 1H); ¹³ C NMR (DMSO-*d*₆) δ 36.49, 58.47, 73.71, 75.25, 76.73, 119.24, 140.00, 149.40, 151.99, 156.04. Calcd. for C₁₀H₁₃N₅O₃: C, 47.80; H, 5.21; N, 27.88. Found: C, 47.92, H, 5.41, N, 27.88.

Acknowledgments

This research was supported by funds from the Department of Health and Human Services (U19-AI31718) and this is appreciated. The anti-HBV assays were supported by contract NO1-AI-45195 between the National Institutes of Allergy and Infectious Disease and Georgetown University and this assistance is also much appreciated.

References

- 1. Shealy, Y. F.; Clayton, J. D. J. Am. Chem. Soc., 1966 88, 3885-3887.
- 2. Borthwick, A. D.; Biggadike, K. Tetrahedron, 1992 48, 571-623.
- 3. Koga, M.; Schneller, S. W., Tetrahedron Lett., 1990 31, 5861-5864.
- For example, (a) Koga, M.; Schneller, S. W. Nucl. Acids Sympos. Ser. 29, 1993 63-65. (b) Siddiqi, S. M.; Chen, X.; Rao, J.; Schneller, S. W.; Ikeda, S.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E. J. Med. Chem., 1995 38, 1035-1038 and references cited therein.
- For example, (a) Dyatkina, N. B.; Theil, F.; von Janta-Lipinski, M. Tetrahedron 1995 51, 761-772. (b) Dyatkina, N. B.; Semizarov, D.; Victorova, L.; Krayevsky, A.; Theil, F.; von Janta-Lipiniski, M. Nucleosides Nucleotides 1995 14, 723-726.
 (c) Borcherding, D. R.; Peet, N. P.; Munson, H. R.; Zhang, H.; Hoffman, P. F.; Bowlin, T. L.; Edwards, C. K., III J. Med. Chem. 1996 39, 2615-2620. (d) Borcherding, D. R.; Butler, B. T.; Linnik, M. D.; Mehdi, S.; Dudley, M. W.; Edwards, C. K., III Nucleosides Nucleotides 1996 15, 967-979.
- Seley, K. L.; Schneller, S. W.; Rattendi, D.; Bacchi, C. J. J. Med. Chem. 1997 40, 622-624.
- Siddiqi, S. M.; Chen, X.; Schneller, S. W. Nucleosides Nucleotides, 1993 12, 267-278.
- Siddiqi, S. M.; Chen, X.; Schneller, S. W.; Ikeda, S.; Snoeck, R.; Andrei, G.; Balzarini, J.; De Clercq, E. J. Med. Chem. 1994 37, 551-554.
- Ness, R. K. in Synthetic Procedures in Nucleic Acid Chemistry, Vol. 1; Zorbach, W. W., Tipson, R. S., eds; John Wiley and Sons: New York, 1968; p.185.
- 10. Korba, B. E.; Gerin, J. L. Antiviral Res. 1992, 19, 55-70.